Zheyuan Technology has completed its Series A2 financing of nearly 200 million yuan.

36Kr learned that Beijing Zheyuan Technology Co., Ltd. has obtained nearly RMB 200 million in its Series A2 financing. This round of financing is led by Sansure Biotech together with its industrial fund, with CAS Star continuing to participate as an existing shareholder, and co-investors including Zhangjiang Sci-Tech Venture Capital. The funds raised in this round will be mainly used for the continuous output of high-value innovative IP and global asset layout, as well as the upgrade of the AI4S platform driven by the life world model.